scispace - formally typeset
S

Savaş Kansoy

Researcher at Ege University

Publications -  49
Citations -  543

Savaş Kansoy is an academic researcher from Ege University. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 14, co-authored 43 publications receiving 444 citations.

Papers
More filters
Journal ArticleDOI

Successful haematopoietic stem cell transplantation in 44 children from healthy siblings conceived after preimplantation HLA matching

TL;DR: Full recovery of 44 sick children who received HSCT from healthy infants conceived after pre-implantation HLA matching for the following 10 indications are reported; beta-thalassaemia, Wiskott-Aldrich syndrome, Fanconi anaemia, sickle cell anaemia), acute myeloid leukaemia, acute lymphoblastic leukaemi, Glanzmann's thrombasthaenia, Diamond-Blackfan anaemia and mucopolysaccharidosis type
Journal ArticleDOI

Radiotherapy-induced secondary cranial neoplasms in children

TL;DR: Patients carry a risk of developing SMNs many years later since irradiation is still an important part of the treatment, and an SMN may have a benign course, as in meningioma, or be a dilemma for the patient, asIn glioblastoma.
Journal ArticleDOI

Hematopoietic cell transplantation in severe combined immunodeficiency: The SCETIDE 2006-2014 European cohort.

Arjan C. Lankester, +59 more
TL;DR: In this paper, the authors performed a comprehensive multicenter analysis of genotype-specific stem cell transplantation including detailed analysis of immune reconstitution (IR) and the predictive value for clinical outcome.
Journal Article

Superiority of oral agar and phototherapy combination in the treatment of neonatal hyperbilirubinemia

TL;DR: Although oral agar was found to be as effective as phototherapy, the most significant decrease in bilirubin level was in the combination group, and Oral agar can also be used as a single agent for the treatment of neonatal hyperbilirubinemia, since it is as effectiveAs phototherapy.
Journal ArticleDOI

Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children

TL;DR: Empirical therapy with meropenem plus amikacin or piperacillin/tazobactam plus netilmicin for high-risk febrile neutropenia is equally effective and safe in pediatric cancer patients.